Estonia - estonio - Ravimiamet

stada arzneimittel ag - losartaan - õhukese polümeerikattega tablett - 12,5mg 100tk; 12,5mg 98tk; 12,5mg 30tk; 12,5mg 28tk; 12,5mg 21tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - tadalafiil - õhukese polümeerikattega tablett - 10mg 20tk; 10mg 4tk; 10mg 16tk; 10mg 24tk; 10mg 28tk; 10mg 30tk; 10mg 12tk; 10mg 60tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - fulvestrant - süstelahus süstlis - 250mg 5ml 5ml 4tk; 250mg 5ml 5ml 1tk; 250mg 5ml 5ml 2tk; 250mg 5ml 5ml 6tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - dabigatraaneteksilaat - kõvakapsel - 150mg 10tk; 150mg 180tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - dabigatraaneteksilaat - kõvakapsel - 75mg 30tk; 75mg 10tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - gemtsitabiin - infusioonilahuse kontsentraat - 38mg 1ml 39.5ml 1tk; 38mg 1ml 5.26ml 1tk; 38mg 1ml 52.6ml 1tk; 38mg 1ml 26.3ml 1tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - posakonasool - gastroresistentne tablett - 100mg 24tk; 100mg 60tk; 100mg 96tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - kabasitakseel - infusioonilahuse kontsentraat - 20mg 1ml 3ml 1tk

Estonia - estonio - Ravimiamet

stada arzneimittel ag - eribuliin - süstelahus - 0,44mg 1ml 2ml 6tk

Unión Europea - estonio - EMA (European Medicines Agency)

stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.